Monte Rosa Therapeutics Files 8-K on Security Holder Vote
Ticker: GLUE · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1826457
| Field | Detail |
|---|---|
| Company | Monte Rosa Therapeutics, Inc. (GLUE) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
Related Tickers: MRSA
TL;DR
Monte Rosa (MRSA) filed an 8-K for a shareholder vote - details TBD.
AI Summary
Monte Rosa Therapeutics, Inc. filed an 8-K on June 13, 2025, to report on the submission of matters to a vote of its security holders. The filing does not disclose specific details about the matters to be voted on or any outcomes.
Why It Matters
This filing indicates a formal process for shareholder decisions is underway, which could impact corporate governance and future strategic directions.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain information that immediately suggests financial or operational risk.
Key Numbers
- 001-40522 — SEC File Number (Identifies the company's filing history with the SEC.)
- 84-3766197 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Monte Rosa Therapeutics, Inc. (company) — Registrant
- June 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Boston, MA (location) — Principal executive offices
FAQ
What specific matters are being submitted for a vote of Monte Rosa Therapeutics' security holders?
The 8-K filing states that the purpose is the 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals or resolutions.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated June 13, 2025.
What is Monte Rosa Therapeutics, Inc.'s state of incorporation?
Monte Rosa Therapeutics, Inc. is incorporated in Delaware.
Where are Monte Rosa Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 321 Harrison Avenue, Suite 900, Boston, MA, 02118.
Is this filing intended to satisfy any other reporting obligations under the Securities Exchange Act of 1934?
The filing includes a checkbox indicating whether it is intended to simultaneously satisfy other provisions, but it is not checked in the provided text, suggesting it is solely for the reported event.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Monte Rosa Therapeutics, Inc. (GLUE).